Mariner
BCRX icon

Mariner’s BioCryst Pharmaceuticals BCRX Stock Holding History

Mariner’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1M Buy
+110,478
New +$999K ﹤0.01% 1862
2026
Q1 		– Sell
-31,495
Closed -$246K – 3573
2025
Q4 		$246K Buy
31,495
+11,807
+60% +$85.4K ﹤0.01% 3013
2025
Q3 		$149K Sell
19,688
-4,761
-19% -$39.6K ﹤0.01% 3278
2025
Q2 		$219K Buy
24,449
+2,805
+13% +$26.1K ﹤0.01% 2983
2025
Q1 		$162K Buy
21,644
+8,386
+63% +$67.6K ﹤0.01% 3070
2024
Q4 		$99.7K Buy
13,258
+3,224
+32% +$24.5K ﹤0.01% 3191
2024
Q3 		$76.3K Buy
+10,034
New +$76.3K ﹤0.01% 3135

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Mariner's BCRX Position: Q2 2026 in Review

Mariner opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 110,478 shares worth $1.1M. The stake represents ﹤0.01% of the portfolio and ranks #1862 among its holdings. This is a return to the name: Mariner previously reported a position in BCRX as recently as Q4 2025.

Mariner first reported a position in BCRX in Q3 2024 and has held it in 7 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Mariner held 110,478 shares of BioCryst Pharmaceuticals worth $1.1M as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Mariner position in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #1862 holding.
  • Mariner first reported a position in BioCryst Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.